| Abstract |
Objective: to analyze and evaluate the clinical efficacy and safety of lurasidone in the treatment of schizophrenia. Methods: 78 patients who met the diagnostic criteria of ICD-10 schizophrenia were randomly divided into lurasidone group (n=38) and risperidone group (n=40). The study lasted for 8 weeks. The total clinical efficacy Rating Scale (CGI GI) and the positive and negative symptom scale (PANSS) were used to evaluate the effective rate and clinical treatment effect at baseline, 2, 4 and 8 weeks, respectively. Treatment compliance was assessed by subjective comfort scale (SWN) at baseline and 8 weeks, and social function recovery was assessed by schihan disability scale (SDS). The safety was evaluated with the adverse drug reaction scale (TESS). Results: there was no significant difference in general data between the two groups at baseline. At the end of the 8th week, the effective rates of lurasidone group and risperidone group were 92.11% and 90.00% respectively. There was no statistical significance between the two groups (p=0.676). There was no statistical difference in PANSS score between the two groups at baseline, and there was no statistical difference in PANSS score between the two groups at 2 weeks, 4 weeks and 8 weeks of treatment. There was statistical difference in PANSS score between the two groups at the end of 8 weeks compared with baseline (t=18.154, P < 0.001 in the study group; t=18.192, P < 0.001 in the control group). There was no significant difference in the scores between the two groups before and after treatment (P > 0.05), and there was significant difference in the SWN scores between the two groups before and after treatment (t=22.394, P < 0.001 in the study group; t=24.230, P < 0.001 in the control group). There was no significant difference in SDS score between the two groups before and after treatment (P > 0.05), but there was significant difference in SDS score between the two groups before and after treatment (t=12.256, P < 0.001 in the study group; t=11.269, P < 0.001 in the control group). No serious adverse drug reactions were found in both groups, and there was no significant difference in the incidence of adverse events between groups (x2/z=0.092, p=0.762). Conclusion: The curative effect of Lurasidone in the treatment of schizophrenia is equivalent to that of risperidone, with high medication compliance and less adverse reactions, which can promote the recovery of social function..
|